Browsing Molecular Pathology by author "Gerlinger, Marco"
Now showing items 1-20 of 26
-
Advances in immunotherapy for MMR proficient colorectal cancer.
Lote, H; Starling, N; Pihlak, R; Gerlinger, M (ELSEVIER SCI LTD, 2022-12-01)Survival in mismatch-repair proficient (MMRp) metastatic colorectal cancer (mCRC) remains poor and chemotherapy is the mainstay of treatment. Immunotherapy has demonstrated durable responses and a favourable side-effect ... -
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.
Gonzalez-Exposito, R; Semiannikova, M; Griffiths, B; Khan, K; Barber, LJ; et al. (BMJ PUBLISHING GROUP, 2019-03-21)BACKGROUND: The T cell bispecific antibody cibisatamab (CEA-TCB) binds Carcino-Embryonic Antigen (CEA) on cancer cells and CD3 on T cells, which triggers T cell killing of cancer cell lines expressing moderate to high ... -
Circulating Tumour DNA Sequencing Identifies a Genetic Resistance-Gap in Colorectal Cancers with Acquired Resistance to EGFR-Antibodies and Chemotherapy.
Knebel, FH; Barber, LJ; Newey, A; Kleftogiannis, D; Woolston, A; et al. (MDPI, 2020-12-11)Epidermal growth factor receptor antibodies (EGFR-Abs) confer a survival benefit in patients with RAS wild-type metastatic colorectal cancer (mCRC), but resistance invariably occurs. Previous data showed that only a minority ... -
Classifying the evolutionary and ecological features of neoplasms.
Maley, CC; Aktipis, A; Graham, TA; Sottoriva, A; Boddy, AM; et al. (NATURE PUBLISHING GROUP, 2017-10-01)Neoplasms change over time through a process of cell-level evolution, driven by genetic and epigenetic alterations. However, the ecology of the microenvironment of a neoplastic cell determines which changes provide adaptive ... -
Comparison of a coaxial versus non-coaxial liver biopsy technique in an oncological setting: diagnostic yield, complications and seeding risk.
Fotiadis, N; De Paepe, KN; Bonne, L; Khan, N; Riddell, A; et al. (SPRINGER, 2020-07-14)OBJECTIVES: Percutaneous liver biopsy (PLB) poses specific challenges in oncological patients such as bleeding and tumour seeding. This study's aim was to compare a coaxial (C-PLB) and non-coaxial (NC-PLB) biopsy technique ... -
Computational Image Analysis of T-Cell Infiltrates in Resectable Gastric Cancer: Association with Survival and Molecular Subtypes.
Challoner, BR; von Loga, K; Woolston, A; Griffiths, B; Sivamanoharan, N; et al. (OXFORD UNIV PRESS INC, 2021-01-04)BACKGROUND: Gastric and gastro-esophageal junction cancers (GCs) frequently recur after resection, but markers to predict recurrence risk are missing. T-cell infiltrates have been validated as prognostic markers in other ... -
Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer.
Lawler, M; Alsina, D; Adams, RA; Anderson, AS; Brown, G; et al. (BMJ PUBLISHING GROUP, 2018-01-01)OBJECTIVE: Colorectal cancer (CRC) leads to significant morbidity/mortality worldwide. Defining critical research gaps (RG), their prioritisation and resolution, could improve patient outcomes. DESIGN: RG analysis was ... -
Defining the true impact of coronavirus disease 2019 in the at-risk population of patients with cancer.
Angelis, V; Tippu, Z; Joshi, K; Reis, S; Gronthoud, F; et al. (ELSEVIER SCI LTD, 2020-09-01)BACKGROUND: In light of the coronavirus disease 2019 (COVID-19) pandemic, cancer centres in the United Kingdom and Europe re-organised their services at an unprecedented pace, and many patients with cancer have had their ... -
Detecting and Tracking Circulating Tumour DNA Copy Number Profiles during First Line Chemotherapy in Oesophagogastric Adenocarcinoma.
Davidson, M; Barber, LJ; Woolston, A; Cafferkey, C; Mansukhani, S; et al. (MDPI, 2019-06-04)DNA somatic copy number aberrations (SCNAs) are key drivers in oesophagogastric adenocarcinoma (OGA). Whether minimally invasive SCNA analysis of circulating tumour (ct)DNA can predict treatment outcomes and reveal how ... -
Development of synchronous VHL syndrome tumors reveals contingencies and constraints to tumor evolution.
Fisher, R; Horswell, S; Rowan, A; Salm, MP; de Bruin, EC; et al. (BMC, 2014-08-27)BACKGROUND: Genomic analysis of multi-focal renal cell carcinomas from an individual with a germline VHL mutation offers a unique opportunity to study tumor evolution. RESULTS: We perform whole exome sequencing on four ... -
Diagnostic Accuracy and Safety of Coaxial System in Oncology Patients Treated in a Specialist Cancer Center With Prospective Validation Within Clinical Trial Data.
Khan, K; Gonzalez-Exposito, R; Cunningham, D; Koh, D-M; Woolston, A; et al. (FRONTIERS MEDIA SA, 2020-09-04)BACKGROUND: Image-guided tissue biopsies are critically important in the diagnosis and management of cancer patients. High-yield samples are also vital for biomarker and resistance mechanism discovery through molecular/genomic ... -
Efficacy and Cardiotoxic Safety Profile of Raltitrexed in Fluoropyrimidines-Pretreated or High-Risk Cardiac Patients With GI Malignancies: Large Single-Center Experience.
Khan, K; Rane, JK; Cunningham, D; Rao, S; Watkins, D; et al. (CIG MEDIA GROUP, LP, 2019-03-01)BACKGROUND: Gastrointestinal (GI) cancer patients may not be considered for therapy with fluoropyrimidines (FPs) because of previous cardiovascular (CV) toxicity or preexisting risk factors; such patients may benefit from ... -
Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer.
von Loga, K; Woolston, A; Punta, M; Barber, LJ; Griffiths, B; et al. (NATURE PUBLISHING GROUP, 2020-01-16)Mismatch repair deficient (dMMR) gastro-oesophageal adenocarcinomas (GOAs) show better outcomes than their MMR-proficient counterparts and high immunotherapy sensitivity. The hypermutator-phenotype of dMMR tumours theoretically ... -
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal Cancer.
Woolston, A; Khan, K; Spain, G; Barber, LJ; Griffiths, B; et al. (CELL PRESS, 2019-06-26)Despite biomarker stratification, the anti-EGFR antibody cetuximab is only effective against a subgroup of colorectal cancers (CRCs). This genomic and transcriptomic analysis of the cetuximab resistance landscape in 35 RAS ... -
Heterogeneous response and progression patterns reveal phenotypic heterogeneity of tyrosine kinase inhibitor response in metastatic renal cell carcinoma.
Crusz, SM; Tang, YZ; Sarker, S-J; Prevoo, W; Kiyani, I; et al. (BIOMED CENTRAL LTD, 2016-11-14)BACKGROUND: Molecular intratumour heterogeneity (ITH) is common in clear cell renal carcinomas (ccRCCs). However, it remains unknown whether this is mirrored by heterogeneity of drug responses between metastases in the ... -
Identifying key questions in the ecology and evolution of cancer.
Dujon, AM; Aktipis, A; Alix-Panabières, C; Amend, SR; Boddy, AM; et al. (WILEY, 2021-02-08)The application of evolutionary and ecological principles to cancer prevention and treatment, as well as recognizing cancer as a selection force in nature, has gained impetus over the last 50 years. Following the initial ... -
Immunopeptidomics of colorectal cancer organoids reveals a sparse HLA class I neoantigen landscape and no increase in neoantigens with interferon or MEK-inhibitor treatment.
Newey, A; Griffiths, B; Michaux, J; Pak, HS; Stevenson, BJ; et al. (BMC, 2019-10-08)BACKGROUND: Patient derived organoids (PDOs) can be established from colorectal cancers (CRCs) as in vitro models to interrogate cancer biology and its clinical relevance. We applied mass spectrometry (MS) immunopeptidomics ... -
Immunotherapy Sensitivity of Mismatch Repair-Deficient Cancer: Mutation Load Is Not Enough.
Gerlinger, M (CELL PRESS, 2021-01-11)Abundant neoantigens are considered responsible for the immunotherapy sensitivity of mismatch repair-deficient (MMRd) cancers. In this issue of Cancer Cell, two papers show that MLH1 mismatch repair gene loss promotes ... -
Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters.
Linch, M; Goh, G; Hiley, C; Shanmugabavan, Y; McGranahan, N; et al. (ELSEVIER, 2017-10-01)BACKGROUND: Intratumoural heterogeneity (ITH) is well recognised in prostate cancer (PC), but its role in high-risk disease is uncertain. A prospective, single-arm, translational study using targeted multiregion prostate ... -
Mutational signatures impact the evolution of anti-EGFR antibody resistance in colorectal cancer.
Woolston, A; Barber, LJ; Griffiths, B; Pich, O; Lopez-Bigas, N; et al. (NATURE PORTFOLIO, 2021-05-20)Anti-EGFR antibodies such as cetuximab are active against KRAS/NRAS wild-type colorectal cancers (CRCs), but acquired resistance invariably evolves. It is unknown which mutational mechanisms enable resistance evolution and ...